The medication is given at the lowest dose to introduce it into the body to help your body adapt to the medication and prevent side effects
GLP-1 medications may not be suitable for individuals with: History of pancreatitis (not recommended per UK SmPCs) Severe gastrointestinal disease or gastroparesis (caution advised) Diabetic retinopathy, particularly for semaglutide (requires monitoring) Pregnancy, planning pregnancy, or breastfeeding (contraindicated
It should be underlined that the beneficial effects resulting from even a 510% weight loss can be invalidated if there is a concomitant exaggerated loss of lean mass
"While the rate of incidence of hair loss is still decidedly low, its a potential trade-off that a patient should consider." "Hair loss was reported more frequently in patients with greater weight loss (20%), suggesting that the events of hair loss were potentially related to the magnitude of weight loss." "Patient safety is of utmost importance to Novo Nordisk," the statement continued
Impressive Weight Reduction: Clinical trials have shown that both Semaglutide and Tirzepatide can lead to remarkable weight loss
